Clinical Trials Logo
  1. Home
  2. Acute Lymphoid Leukemia
  3. NCT00590915
  4. Details
NCT00590915 Clinical Trial

Erwinase Master Treatment Protocol

Acute Lymphoid Leukemia Clinical Trial

— EMTP  

Official title:
Erwinase Master Treatment Protocol

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT00590915
Other study ID # Erwinase
Secondary ID IND-290
Status No longer available
Phase N/A
First received December 26, 2007
Last updated April 11, 2012

Study information
Verified date April 2012
Source Phoenix Children's Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Expanded Access

Clinical Trial Summary

The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.

Other known NCT identifiers
  • NCT01009164

Recruitment information / eligibility
Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patient must give written informed consent to receive Erwinase.

- Patient must be treated for acute lymphoblastic leukemia.

- Patient must have either systemic hypersensitivity reactions to native (Elspar) or pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash with or without anaphylactic symptoms, or patients with previously documented local or systemic reactions to E.coli derived L-asparaginase.

Exclusion Criteria:

- Previous allergic reaction to Erwinia L-asparaginase (Erwinase)

- Previous acute pancreatitis

- Pregnant or lactating woman

Study Design

N/A

Related Conditions & MeSH terms

Intervention

Drug:
• Erwinia L-asparaginase
Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced. NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics.

Locations
Country Name City State
n/a

Sponsors (3)
Lead Sponsor Collaborator
Phoenix Children's Hospital Fisher Bioservices, Jazz Pharmaceuticals
See also
  Status Clinical Trial Phase
Recruiting NCT05959720 - Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Recruiting NCT02933333 - G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Phase 4
Completed NCT02953730 - The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Phase 4
Completed NCT02767388 - Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Recruiting NCT03610438 - Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05792007 - Study of the Medullary Microenvironment in Acute Childhood Leukemia N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01461538 - Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Phase 2
Recruiting NCT04167683 - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Recruiting NCT05150561 - Muscle Dysfunction in Patients With Haematological Diseases
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Recruiting NCT04013685 - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Phase 1
Recruiting NCT02345915 - Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia N/A
Completed NCT01720264 - Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant Phase 2
Not yet recruiting NCT02413021 - The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens Phase 1
Active, not recruiting NCT04778579 - Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy Phase 2
Recruiting NCT03448393 - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Phase 1
Completed NCT03833180 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Phase 1
Active, not recruiting NCT03367299 - Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia Phase 2
Terminated NCT02435550 - iCare for Cancer Patients N/A

External Links